StreetInsider.com News Articles

Zymeworks (ZYME) PT Raised to $33 at JPMorgan

Thu, 03 Sep 2026 08:32:28 -0400

JPMorgan analyst Brian Cheng raised the price target on Zymeworks (NASDAQ: ZYME) to $33.00 (from $31.00) while maintaining a Overweight rating.

Zymeworks (ZYME) PT Raised to $55 at H.C. Wainwright

Wed, 26 Aug 2026 06:45:17 -0400

(Updated - August 26, 2026 6:45 AM EDT)

H.C. Wainwright analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $55.00 (from $51.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Zymeworks' partner, Jazz Pharmaceuticals (JAZZ; Under Review), announced that the FDA approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) regardless of PD-L1 expression: Ziihera plus Tevimbra (tislelizumab) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+). This approval is supported by the

Zymeworks (ZYME) PT Raised to $55 at H.C. Wainwright

Wed, 26 Aug 2026 06:45:17 -0400

(Updated - August 26, 2026 6:45 AM EDT)

H.C. Wainwright analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $55.00 (from $51.00) while maintaining a Buy rating.

Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani

Wed, 26 Aug 2026 04:21:27 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented, "We reiterate our Market Outperform rating on Zymeworks and price target of $32 based on a discounted EPS and revenue multiple analysis. Recently, Zymeworks reported 2Q26 earnings results, and yesterday announced the FDA approval of zanidatamab (zani) in 1L GEA. With zanidatamab royalties to contribute meaningfully in the coming years, ZW191 and ZW251 making steady progress in clinical development, a differentiated pan-RAS inhibitor ADC platform garnering considerable external interest, an ongoing share buy-back program and a solid cash position of $572.5MM

Zymeworks (ZYME) PT Raised to $38 at Citi

Tue, 25 Aug 2026 16:02:10 -0400

Citi analyst Yigal Nochomovitz raised the price target on Zymeworks (NASDAQ: ZYME) to $38.00 (from $37.00) while maintaining a Buy rating.

Form 8-K Zymeworks Inc. For: Aug 25

Tue, 25 Aug 2026 10:54:00 -0400

si-local-file:///var/storage/secattach/20260825/26972714.html

Form 8-K Zymeworks Inc. For: Aug 25

Tue, 25 Aug 2026 10:54:00 -0400

si-local-file:///var/storage/secattach/20260825/26972714.html

Zymeworks Announces Participation in Upcoming Investor Conferences

Tue, 11 Aug 2026 06:00:00 -0400

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA.
Citi’s Biopharma Back to School Summit: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York,

Zymeworks Announces Participation in Upcoming Investor Conferences

Tue, 11 Aug 2026 06:00:00 -0400

Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA.
Citi’s Biopharma Back to School Summit: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York,

Zymeworks (ZYME) PT Raised to $44 at B.Riley

Mon, 10 Aug 2026 08:18:52 -0400

B.Riley analyst Mayank Mamtani raised the price target on Zymeworks (NASDAQ: ZYME) to $44.00 (from $40.00) while maintaining a Buy rating.

Zymeworks (ZYME) PT Lowered to $46 at Stifel

Fri, 07 Aug 2026 10:29:56 -0400

Stifel analyst Stephen Willey lowered the price target on Zymeworks (NASDAQ: ZYME) to $46.00 (from $47.00) while maintaining a Buy rating.

Zymeworks (ZYME) PT Raised to $40 at Wells Fargo

Fri, 07 Aug 2026 08:23:54 -0400

Wells Fargo analyst Eva Verdejo raised the price target on Zymeworks (NASDAQ: ZYME) to $40.00 (from $37.00) while maintaining a Overweight rating.

Zymeworks (ZYME) Misses Q2 EPS by 25c

Thu, 06 Aug 2026 17:35:55 -0400

Zymeworks (NASDAQ: ZYME) reported Q2 EPS of ($0.62), $0.25 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $19.1 million.

For earnings history and earnings-related data on Zymeworks (ZYME) click here.

Form 10-Q Zymeworks Inc. For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884058.html

Form 10-Q Zymeworks Inc. For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884058.html

Form 8-K Zymeworks Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883884.html

Form 8-K Zymeworks Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883884.html

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results